Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Severe Asthma
Phase Not Applicable
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

Severe asthma is a disease characterised by respiratory and non-respiratory symptoms. The respiratory symptoms can include breathlessness, wheeze and asthma attacks. The disease can come to dominate patients' lives, impacting their social, working and personal lives, leading to depression, anxiety and feelings of social isolation. There are now 7 different biologic treatments available on the NHS in the UK for severe asthma. These treatments have dramatically changed how severe asthma can be treated. Research has typically focused on the benefits of these drugs from a clinical perspective, e.g., improvements in lung function, blood tests and reduction in frequency of asthma attacks and use of steroid tablets. While these are important outcomes, they do not reflect the experiences of patients receiving these treatments, which can vary greatly. First, not all patients benefit to the same degree. Second for patients who do respond, some respond slower than others. Third while these treatments target respiratory symptoms, some patients report wider benefits, such as reductions in fatigue, depression, ability to engage in family life and other daily activities. Fourth, patients report different side effects when starting these treatments and sometimes for months afterwards, including headaches, fatigue, mental fog and joint pain. These experiences are reported by clinicians and patients, but the extent of these four variations is poorly understood, and potential reasons for them have not been explored. To describe these differences between patients' experiences and begin understanding why they are present, we have co-designed a survey with people who have lived experience of severe asthma who are members of the European Lung Foundation's (ELF) Patient Advisory Group (PAG). This process has resulted in a survey that contains content important to patients and is worded in a way that avoids confusion regarding the meaning of the questions.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Interventions / Regimen

  • Other: Survey using a questionnaire. — A short 23-item survey concerning patients' experiences of their biologic treatments for their severe asthma.

Primary Outcomes

  • Severe asthma biologic experience survey (6-18 month recall)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-01-01
Completion: 2025-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Royal Devon and Exeter NHS Foundation Trust
Collaborators: University of Plymouth, University Hospital Plymouth NHS Trust, Newcastle-upon-Tyne Hospitals NHS Trust, University Hospital Birmingham, Barts & The London NHS Trust, Guy's and St Thomas' NHS Foundation Trust
Principal Investigators:
  • Matthew Masoli, MD (PRINCIPAL_INVESTIGATOR) - Royal Devon and Exeter NHS Foundation Trust
Contact Information
Study Contact:
Joseph Lanario, PhD
+44 01752 764403
joseph.lanario@plymouth.ac.uk
Alison Kerridge, PhD
+44 01392 403055
alison.kerridge@nhs.net
Joseph Lanario, PhD
01752 764403
joseph.lanario@plymoyth.ac.uk
Royal Devon University Healthcare NHS Foundation Trust
Interventions
  • Other: Survey using a questionnaire. — A short 23-item survey concerning patients' experiences of their biologic treatments for their severe asthma.
Study Locations (1 sites)
Royal Devon University Healthcare NHS Foundation Trust, Exeter, Devon EX2 5DW United Kingdom
Eligibility Criteria
Inclusion Criteria: Receiving a biologic treatment for at least 6 months. • But has not been on the treatment for longer than 18 months. Note: In clinical practice, a 12-month trial of biologic treatments is needed before a decision to stop/switch treatment is made. Therefore, our inclusion criteria will capture people who are non-responders to biologic treatments. Exclusion Criteria: * Patients will be excluded if they are unwilling/unable to provide consent to use their data. * Patients who have switched biologics will also be excluded. * In the opinion of the physician responsible for the care of the patient, the patient has a condition, other than asthma which is significantly contributing to their respiratory symptoms, e.g. lung cancer, heart failure or severe COPD.
Conditions Asthma (Diagnosis), Chronic Obstructive ...
Phase Not Applicable
Enrollment 950
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

This research study focuses on chronic airway diseases, such as Chronic Obstructive Pulmonary Disease (COPD) and asthma. These conditions make it difficult for patients to breathe, but breathing difficulty (dyspnea) is often perceived very differently. Some patients may feel severe distress with mild breathing problems, while others might not notice significant breathing issues even when lung function is poor. This difference in perception is termed "dyspnea perception." The main goal of this study is to understand how dyspnea perception varies among patients with chronic airway diseases. The investigators aim to determine if patients can be grouped into different subtypes based on the perception of breathing difficulties. The study will also investigate how these subtypes relate to other treatable characteristics, such as blood cell counts, allergy test results, and findings from lung function tests and brain scans. Approximately 800 patients with COPD or asthma and 150 healthy volunteers will participate. Participants will answer questionnaires, undergo lung function tests, provide blood samples, and a subset will undergo a special brain scan (functional MRI). No new treatments will be assigned; instead, these characteristics will be observed and measured over time. It is hoped that this study will help doctors better understand chronic airway diseases and lead to more personalized management strategies for patients in the future.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Comprehensive Clinical Assessment — This is an observational study. No interventional treatment is assigned. Participants will undergo a comprehensive clinical assessment protocol, which includes: Measurement of dyspnea perception using standardized scales. Spirometry, lung volume, and diffusion capacity tests. Blood sample collection for complete blood count, total IgE, and allergen-specific IgE screening. Completion of quality of life and respiratory symptom questionnaires (e.g., CAT, mMRC, SGRQ, AQLQ). Fractional exhaled nitric oxide (FeNO) measurement. High-resolution computed tomography (HRCT) of the chest. Functional magnetic resonance imaging (fMRI) of the brain (for a subset of participants). Data on exacerbation history, comorbidities, and current medications will also be collected.

Primary Outcomes

  • Distribution of Dyspnea Perception Scores (Baseline)
  • Clinical Phenotypes Based on Dyspnea Perception (Through study completion, an average of 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-05-07
Completion: 2027-12
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: true
Enrollment: 950 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Beijing Chao Yang Hospital
Principal Investigators:
  • Kewu Huang, M.D. (PRINCIPAL_INVESTIGATOR) - Beijing Chao Yang Hospital
Contact Information
Study Contact:
Shuya Huang, M.D.
+8617852063100
17852063100@163.com
ZIxuan Wu, Master
+8617734128891
17734128891@163.com
Shuya Huang, M.D.
+8617852063100
17852063100@163.com
Beijing Chao-Yang Hospital
Interventions
  • Other: Comprehensive Clinical Assessment — This is an observational study. No interventional treatment is assigned. Participants will undergo a comprehensive clinical assessment protocol, which includes: Measurement of dyspnea perception using standardized scales. Spirometry, lung volume, and diffusion capacity tests. Blood sample collection for complete blood count, total IgE, and allergen-specific IgE screening. Completion of quality of life and respiratory symptom questionnaires (e.g., CAT, mMRC, SGRQ, AQLQ). Fractional exhaled nitric oxide (FeNO) measurement. High-resolution computed tomography (HRCT) of the chest. Functional magnetic resonance imaging (fMRI) of the brain (for a subset of participants). Data on exacerbation history, comorbidities, and current medications will also be collected.
Study Locations (1 sites)
Beijing Chao-Yang Hospital, Beijing, Beijing Municipality China
Eligibility Criteria
Inclusion Criteria: * Inclusion Criteria for Chronic Airway Disease Patients: 1. Age 20-75 years. 2. Meets the diagnostic criteria for COPD according to the 2022 GOLD guidelines OR meets the diagnostic criteria for asthma according to the 2022 GINA guidelines. 3. Willing and able to provide informed consent. * Inclusion Criteria for Healthy Controls: 1. Age ≥20 years. 2. No history of asthma symptoms or diagnosis of chronic respiratory diseases such as asthma or COPD. 3. Willing and able to provide informed consent and comply with the study protocol. Exclusion Criteria: * (applies to all participants): 1. Respiratory tract infection, COPD acute exacerbation, or asthma acute exacerbation within the past 3 months. 2. Presence of other diseases causing significant lung tissue destruction, such as severe bronchiectasis or tuberculosis. 3. History of thoracic or abdominal surgery within the past 3 months. 4. Heart rate \>120 beats per minute. 5. Ongoing anti-tuberculosis treatment. 6. Presence of other severe, uncontrolled systemic diseases. 7. Pregnant or lactating women.
Conditions Depression, Major Depressive Disorder
Phase NA
Enrollment 320
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

Researchers hope to see if the data smartphones collect continuously can be used to predict if patient's depression symptoms will return. They will do this by collecting data from patient's smartphones and comparing it to their depression symptoms. If this method is successful, researchers could develop a smartphone application to help healthcare providers better monitor patient's depression and intervene earlier if symptoms return.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Other: MoodTriggers Application — The Mood Triggers application, developed by Dr. Jacobson, will be used for collecting smartphone sensor data. This HIPAA-compliant app has been incorporated into various projects at Dartmouth, Stanford, and MGH/Harvard, with development supported by NIDA, NIMHD, NCI, and the Department of Veterans Affairs. The Mood Triggers app will capture a wide range of metrics, including psychomotor agitation, sleep disturbances, low behavioral activation, social contact, exposure to natural light, heart rate, heart rate variability, and screen time. The app also tracks the patient's screen time and app usage data. The Mood Triggers App will be installed on the smartphones at time of informed consent for all 120 patients enrolled in Phase 1 and for 100 clinical trial participants randomized to the "early warning system" (intervention arm) in Phase 2. Data will be collected from the Mood Triggers App starting on day of discharge from care and for 6 months post-discharge date.

Primary Outcomes

  • Monthly depression relapse (discharge, 6-months post-discharge)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-20
Completion: 2028-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 320 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dartmouth-Hitchcock Medical Center
Collaborators: National Center for Advancing Translational Sciences (NCATS)
Principal Investigators:
  • Nicholas C Jacobson, PhD (PRINCIPAL_INVESTIGATOR) - Dartmouth College
Contact Information
Study Contact:
Nicholas C Jacobson, PhD
(603) 646-7037
nicholas.c.jacobson@dartmouth.edu
Nicholas C Jacobson, PhD
(603) 646-7037
nicholas.c.jacobson@dartmouth.edu
Dartmouth College
Nicholas C Jacobson, PhD
(603) 646-7037
nicholas.c.jacobson@dartmouth.edu
Dartmouth-Hitchcock Clinics
Interventions
  • Other: MoodTriggers Application — The Mood Triggers application, developed by Dr. Jacobson, will be used for collecting smartphone sensor data. This HIPAA-compliant app has been incorporated into various projects at Dartmouth, Stanford, and MGH/Harvard, with development supported by NIDA, NIMHD, NCI, and the Department of Veterans Affairs. The Mood Triggers app will capture a wide range of metrics, including psychomotor agitation, sleep disturbances, low behavioral activation, social contact, exposure to natural light, heart rate, heart rate variability, and screen time. The app also tracks the patient's screen time and app usage data. The Mood Triggers App will be installed on the smartphones at time of informed consent for all 120 patients enrolled in Phase 1 and for 100 clinical trial participants randomized to the "early warning system" (intervention arm) in Phase 2. Data will be collected from the Mood Triggers App starting on day of discharge from care and for 6 months post-discharge date.
Study Locations (2 sites)
Dartmouth College, Hanover, New Hampshire 03755 United States
Dartmouth-Hitchcock Clinics, Lebanon, New Hampshire 03766 United States
Eligibility Criteria
Inclusion Criteria: * Adult patients (18 years or older) * Treated for depression within Dartmouth Health collaborative care model (CoCM) sites who are discharged from CoCM without depression (PHQ-9 \< 10) * Have access to and ability to use a smartphone (Android version ≥ 6 or iOS version ≥ 11). Exclusion Criteria: * Identified as high risk due to active suicidality, psychosis, or bipolar disorder - Discharged from CoCM with ongoing depressive symptoms (PhQ-9 \> 10
Conditions Major Depressive Disorder
Phase NA
Enrollment 12
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

Neurons are specialized types of cells that are responsible for carrying out the functions of the brain. Neurons communicate with electrical signals. In diseases such as major depression this electrical communication can go awry. One way to change brain function is using electrical stimulation to help alter the communication between groups of neurons in the brain. The purpose of this study is to test a personalized approach to brain stimulation as an intervention for depression. The study researchers will use a surgically implanted device to measure each individual's brain activity related to his/her depression. The researchers will then use small electrical impulses to alter that brain activity and measure whether these changes help reduce depression symptoms. This study is intended for patients with major depression whose symptoms have not been adequately treated with currently available therapies. The device used in this study is called the NeuroPace Responsive Neurostimulation (RNS) System. It is currently FDA approved to treat patients with epilepsy. The study will test whether personalized responsive neurostimulation can safely and effectively treat depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: Stimulation-ON — Active neurostimulation from the NeuroPace RNS® System triggered by a biomarker
  • Device: Stimulation-OFF — No neurostimulation from the NeuroPace RNS® System
  • Device: Stimulation-ON Active Control — Active neurostimulation from the NeuroPace RNS® System triggered by a sham biomarker

Primary Outcomes

  • change in MADRS score (administered at baseline and every 2 weeks for the first 18 weeks of stage 3)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2019-07-18
Completion: 2035-06-28
Eligibility
Age: 22 Years and older
Sex: ALL
Volunteers: false
Enrollment: 12 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Andrew Krystal
Principal Investigators:
  • Andrew Krystal, MD, MS (PRINCIPAL_INVESTIGATOR) - University of California, San Francisco
Contact Information
Study Contact:
Katherine Scangos, MD, PhD
415-476-7439
trdepression@ucsf.edu
Rebecca Martinez, MS
415-476-7439
rebecca.martinez@ucsf.edu
Katherine Scangos, MD, PhD
415- 476-7439
trdepression@ucsf.edu
University of California, San Francisco
Interventions
  • Device: Stimulation-ON — Active neurostimulation from the NeuroPace RNS® System triggered by a biomarker
  • Device: Stimulation-OFF — No neurostimulation from the NeuroPace RNS® System
  • Device: Stimulation-ON Active Control — Active neurostimulation from the NeuroPace RNS® System triggered by a sham biomarker
Study Locations (1 sites)
University of California, San Francisco, San Francisco, California 94143 United States
Eligibility Criteria
Inclusion Criteria: * Age 22-70 * Meet the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) diagnostic criteria for Major Depressive Disorder (MDD) without psychosis based on a Structured Clinical Interview for DSM-V (SCID) with current episode ≥ 2 years that is treatment- resistant (4 adequate trials (including ECT), 3 classes of medications, one augmentation strategy, psychotherapy) as measured by the antidepressant treatment history form (ATHF). * Failed electroconvulsive therapy (ECT) due to inability to achieve sustained response (2 failed attempts to discontinue ECT treatment) or discontinued due to intolerable side effects. * Has MADRS score of \> 26 at both baseline and screening visit * The presence of variability on repeated administrations of MDD rating scales (minimum of 2-point variation on the HAMD-6 administered 3 times a day for 3 days), which is required for the identification of a neural biomarker. * If patient is on a regimen of psychotropic medication, no changes in this regimen should be made during the 4 weeks prior to entry into and the duration of the study. * Willing and able to undergo invasive brain recording/stimulation study * Willing and able to attend multiple research visits and perform at-home research protocol * Willing and able to provide informed consent * Ability to speak and read English Exclusion Criteria: * Meets DSM-V criteria for a psychotic disorder, eating disorder, panic disorder, posttraumatic stress disorder, bipolar disorder, obsessive compulsive disorder, tic disorder, or another comorbid psychiatric disorder other than MDD or generalized anxiety disorder based on a SCID * Generalized anxiety disorder is the primary DSM-V disorder during the current MDD episode * Active suicidal ideation with intent and plan as defined by a score of 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) * History of suicide attempt requiring hospitalization in previous 2 years. * Meets criteria for alcohol or substance abuse or dependence (other than caffeine) in previous 6 months, determined by the SCID * Has a personality disorder based on the investigator's assessment that the investigator believes will adversely impact subject compliance or safety * Fibromyalgia or chronic fatigue syndrome * Current condition requiring chronic narcotic use * History of traumatic brain injury, another neurological disorder, or developmental delay * History of seizures * MRI (done within one year of the first visit) with significant abnormalities * Previous ablative intracranial surgery or previously implanted deep brain stimulation system or any previously implanted device treatment involving brain stimulation * Implantable hardware not compatible with MRI or with the study * Major medical co-morbidities increasing the risk of surgery including severe diabetes, major organ system failure, history of hemorrhagic stroke, need for chronic anticoagulation other than aspirin, active infection, intracranial space occupying lesion, increased intracranial pressure, cardiovascular accident within the last month, aneurysm/abnormality, retinal detachment, unstable cardiovascular disease (recent myocardial infarction, severe ischemia, severe or uncontrolled hypertension), immunocompromised state, or malignancy with \< 5 years life expectancy * Inability to stop Coumadin or platelet anti-aggregation therapy for surgery and after surgery. - Patients taking these medications will need to discuss the need/risk of continuing these medications with their physicians and the PI or study personnel may contact the treating physician(s) to discuss the risks of anticoagulation/antiaggregation therapy discontinuation * Coagulopathy. Patients will be excluded unless assessed and cleared by hematology * Allergies or known hypersensitivity to materials in the NeuroPace RNS® System (i.e. titanium, polyurethane, silicone, polyetherimide, stainless steel) * Subject lives alone without possibility of caregiver support post-hospital stay * Inability to comply with study follow-up visits * Women who are pregnant, plan to become pregnant, or breast feeding * Inability to speak and/or read English * Inability to give consent * Significant cognitive impairment or dementia (MoCA \< 25) * Likely to require ECT during the course of the study
Conditions Depression, Anxiety, Anger, Parenting, S...
Phase NA
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

Children are highly sensitive to adversity during their first five years of life, with exposure to chronic parental mental illness (MI) consistently linked to socio-emotional impairments and mental health problems in children. Children born during the COVID-19 pandemic were exposed to unprecedented level of parental distress, with parental MI reported at three times the pre-pandemic rates. This situation underscored a pressing need for scalable solutions to foster positive mental health and developmental outcomes for a generation of children. In response, the investigators developed the Building Emotional Awareness and Mental Health (BEAM) program, an innovative mobile health (mHealth) solution for parents of young children. Clinical trials to date evaluating BEAM have shown promising results, demonstrating reductions in parent depression, anxiety, and harsh parenting practices. This trial involves an effectiveness-implementation hybrid design with co-primary aims of (1) determining BEAM's effectiveness in improving child mental health and developmental outcomes, and (2) evaluating the implementation of BEAM in the community through metrics such as feasibility, acceptability, and uptake. The secondary aim of this trial is to measure BEAM's effectiveness in improving long-term biopsychosocial family outcomes using administrative data. A final exploratory aim of this trial will measure the cost-utility of delivering BEAM relative to extant health programming. This trial will evaluate the effectiveness of implementing the BEAM intervention in the community with a sample of 400 parent participants with a child aged 24-71 months. Study participants will complete 12 weeks of psychoeducation modules in the BEAM app, with access to an online social support forum and check ins with a peer coach. Assessments of parent and child symptoms will occur at pre-test before BEAM begins (T1), immediately after the last week of the BEAM intervention (post-test, T2), 6-month follow-up (T3), and 12-month follow-up (T4). Beginning in 2025, the trial offers participants the option to invite one parenting partner to join them in the program. A parenting partner is defined as a co-parent (e.g., the child's mother, father, or step-parent) or another primary caregiver (e.g., a grandparent, cousin, uncle, or aunt). Each participant may invite one such individual, hereafter referred to as a "co-parent." Co-parents will have access to the BEAM intervention and all its features, with the exception of peer coaching. Co-parents will be eligible to complete the same outcome measures at the same timepoints as participants. Three differences that will separate co-parents from participants are: (1) co-parents will not be asked to complete the ASQ:2-SE or ASQ-3 secondary outcome measures; (2) co-parents will not have access to peer coaching, and (3) co-parents will not be required to be experiencing moderate to severe symptoms of depression, anxiety, parenting stress, and/or anger…

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: The Building Emotional Awareness and Mental Health (BEAM) Program — The BEAM Program builds on mHealth best practices and evidence-based program design principles with the core objectives of improving maternal mental health and fostering supportive parenting. Program content draws on transdiagnostic emotion-focused mental health and third wave Cognitive Behavioural Therapy principles such as Dialectical Behavioural Therapy, Acceptance and Commitment Therapy, and the Unified Protocol. Program delivery will be facilitated through a mobile application. The BEAM program uses a stepped care model to address the pressing need for accessible and effective mental health interventions. Stepped care is a framework that provides mental health services in a tiered manner, ensuring that participants receive appropriate levels of support based on the severity of needs. At the heart of this model are BEAM peer coaches, who will have the most direct contact with participants. Peer coaches are trained to escalate concerns to the program clinical team as required.

Primary Outcomes

  • Change in parent mental health symptom composite. (All measures to be assessed pre-intervention (T1), immediately after intervention (T2), at 6-month follow-up (T3), and at 12-month follow-up (T4).)
  • Feasibility of the BEAM program. (To be assessed immediately after intervention (T2).)
  • Acceptability and uptake of the BEAM program. (To be assessed pre-intervention (T1), during intervention, and immediately after intervention (T2).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-03-11
Completion: 2027-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Leslie E. Roos
Collaborators: Canadian Institutes of Health Research (CIHR), Manitoba Centre for Health Policy, George & Fay Yee Centre for Healthcare Innovation, Children's Hospital Research Institute of Manitoba, Family Dynamics, Manitoba, Canada
Principal Investigators:
  • Leslie E Roos, PhD (PRINCIPAL_INVESTIGATOR) - University of Manitoba
Contact Information
Study Contact:
Leslie E Roos, PhD
2044747400
leslie.roos@umanitoba.ca
Maryem Zahra Project Coordinator, Bachelor of Arts (Hon)
Maryem.Zahra@umanitoba.ca
Leslie E Roos, PhD
2044747400
leslie.roos@umanitoba.ca
University of Manitoba - Department of Psychology & Pediatrics
Interventions
  • Behavioral: The Building Emotional Awareness and Mental Health (BEAM) Program — The BEAM Program builds on mHealth best practices and evidence-based program design principles with the core objectives of improving maternal mental health and fostering supportive parenting. Program content draws on transdiagnostic emotion-focused mental health and third wave Cognitive Behavioural Therapy principles such as Dialectical Behavioural Therapy, Acceptance and Commitment Therapy, and the Unified Protocol. Program delivery will be facilitated through a mobile application. The BEAM program uses a stepped care model to address the pressing need for accessible and effective mental health interventions. Stepped care is a framework that provides mental health services in a tiered manner, ensuring that participants receive appropriate levels of support based on the severity of needs. At the heart of this model are BEAM peer coaches, who will have the most direct contact with participants. Peer coaches are trained to escalate concerns to the program clinical team as required.
Study Locations (1 sites)
University of Manitoba - Department of Psychology & Pediatrics, Winnipeg, Manitoba R3T 2N2 Canada
Eligibility Criteria
Inclusion Criteria: 1. Moderate to severe symptoms of depression, anxiety, parenting stress, and/or anger (as measured by the PHQ-9, GAD-7, PSI, and PROMIS-Anger). Those who do not have moderate to severe symptoms will meet with a member of the program research team to determine eligibility. This eligibility decision will be based on clinical judgement, ensuring that those with need can participate. 2. Being a parent or primary caregiver of any gender to an 24- to 71-month-old (i.e., 2-5 year old) child. 3. Living in Manitoba. 4. Able to participate in check ins (15 to 60 minutes) via Zoom, phone, direct messaging with a parent peer coach. 5. 18 years or older. 6. Able to understand/read/speak in English. 7. Willing to complete four 45-min questionnaires. 8. At eligibility screening, a question asks if participants have access to an electronic device for viewing videos and participating in Zoom meetings. Participants who do not have access will be asked to contact the research team. The team may be able to accommodate a limited number of participants by providing relevant devices for the duration of the study. 9. Participants have IP addresses within Manitoba, Canada, as determined by IP address in REDCap at time of eligibility screener questionnaire completion. Participants will be required to securely upload a photo that includes both a valid piece of Manitoba government identification and the participant's face (i.e., a 'selfie'). Exclusion Criteria: 1. Living outside of Manitoba. 2. Being a parent or primary caregiver to a child outside of the ages of 24- to 71-months (i.e., 2-5 years). 3. Previously participated in an earlier BEAM trial. 4. Parents who report self-harm that required medical attention within the past six months or a suicide attempt within the past year will be ineligible to participate in BEAM unless the participant is engaged in individual therapy that attends to this acute risk level with one of the following professionals for the duration of the BEAM program: psychiatrist, psychologist, social worker, or psychotherapist. The research team will email all prospective participants who are pending eligibility to schedule a phone call. This call will determine whether it is feasible to connect the participant with an individual therapist to manage specific needs before engaging in the BEAM program, and discuss if the BEAM program is the right fit for the participant's present needs. Co-parents will be permitted to participate in BEAM regardless of current mental health challenges. Therefore, co-parents are only subject to inclusion criterion (3) and criteria (5-9). Instead of meeting inclusion criteria (2), parenting partners must be a "co-parent (e.g., the child's mom, dad, step-parent) or other primary caregiver (e.g., the child's grandma, cousin, uncle, auntie)" to the corresponding participant's 24- to 71-month-old (i.e., 2-5 year old) child. Co-parents will not receive the same pre-trial screening as parent participants, and thus will not be subject to exclusion criteria.
Conditions Treatment Resistant Depression
Phase PHASE3
Enrollment 31
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

Depression is a common condition, with serious negative effects on the health and quality of life of those affected. While there are currently various medications which attempt to treat depression, they often take a long time to begin to work and do not work at all for many people. There is therefore a need for new treatments which work quickly and effectively. One such medication is called ketamine. Studies have shown that ketamine can treat symptoms of depression quickly. This quick action sets ketamine apart from many antidepressants that take weeks to show noticeable effects. One way that it may do this is by creating a transient sense or feeling of being separated from reality, such as seeing or hearing things that are not really there. Another way to create these same feelings is with virtual reality (VR), where a person can feel as though they are entering a 3-dimensional virtual computer-generated world by wearing a special headset or goggles with a computer inside. In this study, all participants will receive standard ketamine treatments for depression. Half of the participants will also use a VR headset while receiving the ketamine treatments to see if ketamine and VR acting together provide a better treatment for symptoms of depression than ketamine alone. This is a small pilot trial. The main purpose of this trial is to learn if it is possible to run a larger clinical trial comparing "ketamine and VR" with "ketamine alone", for adults with treatment-resistant depression. The researchers will study this by seeing how many participants take part in the study within 1-2 years, and how many complete the study treatments and tests. The researchers will also compare the two study groups to see if "ketamine and VR" provide a better treatment for symptoms of depression than "ketamine alone".

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Ketamine — Standard-of-care ketamine treatment in the outpatient setting: 0.5 mg/kg IV infused over 45 minutes (with monitoring up to 90 minutes) per session, with 2 sessions per week for 2 weeks (total 4 treatments).
  • Device: Oculus VR headset — Immersion in 45 minutes of virtual environments using the Oculus VR headset during each ketamine infusion.

Primary Outcomes

  • Feasibility - Number of Participants who Complete at least 90% of Study Follow-ups (From enrolment until the end of follow-ups at 3 months)
  • Feasibility - Time Required to Complete Enrolment (At the time of enrolment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-05-03
Completion: 2028-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 31 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sunnybrook Health Sciences Centre
Contact Information
Study Contact:
Fahad Alam, MD
416-480-4864
fahad.alam@sunnybrook.ca
Peter Giacobbe, MD
416-480-4085
peter.giacobbe@sunnybrook.ca
Fahad Alam, MD
(416) 480-4864
fahad.alam@sunnybrook.ca
Sunnybrook Health Sciences Centre
Interventions
  • Drug: Ketamine — Standard-of-care ketamine treatment in the outpatient setting: 0.5 mg/kg IV infused over 45 minutes (with monitoring up to 90 minutes) per session, with 2 sessions per week for 2 weeks (total 4 treatments).
  • Device: Oculus VR headset — Immersion in 45 minutes of virtual environments using the Oculus VR headset during each ketamine infusion.
Study Locations (1 sites)
Sunnybrook Health Sciences Centre, Toronto, Ontario M4N 3M5 Canada
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18, able to provide informed consent * Patient diagnosed with treatment-resistant depression * Outpatient recommended and approved by psychiatrist for ketamine treatment * Patients who are on IV ketamine and requiring at least 4 treatments of IV ketamine per course (prescribed by their physiatrist) * Cognitively alert, oriented, and able to watch immersive content and respond to questions * Negative human chorionic gonadotropin test before treatment, for female participants of childbearing potential who are not practicing medically appropriate methods of birth control (e.g., hormonal contraceptives, implants, injectables, intrauterine devices, intrauterine systems, etc.) Exclusion Criteria: * History of psychosis/comorbid psychiatric disorders/psychotic depression/dissociative syndromes, significant personality disorder, as clinically assessed by psychiatrist * Using non-prescribed substance (e.g., cannabis) or alcohol use within the preceding 48 hours of treatment * History of substance misuse and/or dependence, including chronic alcohol abuse * Previous ketamine use * Acute dementia/delirium * Acute risk of suicide at baseline, as determined by the study psychiatrist * Pregnancy/breastfeeding * Previous sensitivity to ketamine or related compounds * Unstable medical condition which may require anesthesia consult * History of elevated intracranial pressure or cerebrovascular accident * Recent (within 6 weeks) major cardiovascular event (such as myocardial infarction) * Significant motion sickness (i.e. occur during exposure to physical/visual and virtual motion, cybersickness, etc.) self-identified by patient * Inability to communicate with the study team
Conditions Postpartum Depression, Postpartum Disord...
Phase NA
Enrollment 98
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this study is to design and validate an online intervention aimed at promoting well-being in women with postpartum depression. For this, the design of a multicomponent protocol consisting of empirically validated positive interventions and comparing these with a group Cognitive Behavioral Therapy (CBT) is proposed, following the National Institute for Health and Care Excellence (NICE) recommendations for the treatment of depression. Participants will be screened for inclusion in the program if they meet clinical criteria. After that, they will be randomly assigned to a CBT group or a positive psychology intervention (PPI) group.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Positive Psychology Intervention — PPI includes 2 modules: hedonic well-being and eudaimonic well-being.
  • Behavioral: Cognitive Behavior Therapy — CBT includes 3 modules: behavioral activation, cognitive restructuring, and interpersonal skills.

Primary Outcomes

  • Postpartum depression change (Immediately before and after the intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-01-16
Completion: 2026-03-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 98 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universidad Complutense de Madrid
Collaborators: Universidad Pontificia de Salamanca
Principal Investigators:
  • Covadonga Chaves, PhD (PRINCIPAL_INVESTIGATOR) - Universidad Complutense de Madrid
Contact Information
Study Contact:
Covadonga Chaves
+34635321643
cchavesv@psi.ucm.es
Covadonga Chaves Vélez
+36 635321643
cchavesv@psi.ucm.es
Covadonga Chaves Vélez
Almudena Duque
aduquesa@upsa.es
Covadonga Chaves Vélez
Interventions
  • Behavioral: Positive Psychology Intervention — PPI includes 2 modules: hedonic well-being and eudaimonic well-being.
  • Behavioral: Cognitive Behavior Therapy — CBT includes 3 modules: behavioral activation, cognitive restructuring, and interpersonal skills.
Study Locations (1 sites)
Covadonga Chaves Vélez, Madrid, Pozuelo de Alarcón 28223 Spain
Eligibility Criteria
Inclusion Criteria: * Women who have been mothers in the last year Exclusion Criteria: * Women who have been mothers in the last month, * Women who meet the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for substance abuse and/or dependence within 30 days prior to study participation, * Women who have a serious mental disorder that makes it difficult to follow the protocol (e.g. serious neurocognitive problems or brain damage; schizophrenia and other psychotic disorders).
Conditions Depression, Anxiety, Burnout, Student
Phase NA
Enrollment 250
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate an intervention for improving Science, Technology, Engineering, and Math (STEM) graduate student wellbeing. Participants will be recruited from the University of Wisconsin-Madison graduate student body. Data will be collected from participants for up to 2 years, and the investigators anticipate that the study will last for 4 years.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Behavioral: Mindfulness Practice — Participants follow guided meditations in the Healthy Minds Program (HMP) mobile phone app for at least 15 min per day, for a total of 14 days.
  • Behavioral: Storytelling Workshop — Participants attend 1 (120 min) workshops, teaching them creative writing tools and giving them opportunities to apply those tools.

Primary Outcomes

  • Change from Baseline in Five Facet Mindfulness Questionnaire at 4 weeks (Baseline and 4 weeks)
  • Change from Baseline in Perceived stress scale at 4 weeks (Baseline and 4 weeks)
  • Change from Baseline in WHO-5 Well-being Index at 4 weeks (Baseline and 4 weeks)
  • Change from Baseline in PROMIS Depression Questionnaire at 4 weeks (Baseline and 4 weeks)
  • Change from Baseline in PROMIS Anxiety Questionnaire at 4 weeks (Baseline and 4 weeks)
  • Change from Baseline in PROMIS Sleep Disturbance Questionnaire at 4 weeks (Baseline and 4 weeks)
  • Change from Baseline in PROMIS Global Health Questionnaire at 4 weeks (Baseline and 4 weeks)
  • Change from Baseline in Vanderweele Flourishing Measure at 4 weeks (Baseline and 4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-03-10
Completion: 2027-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Wisconsin, Madison
Principal Investigators:
  • Jo Handelsman, PhD (PRINCIPAL_INVESTIGATOR) - University of Wisconsin, Madison
Contact Information
Study Contact:
Jo Handelsman, PhD
608-695-0093
jo.handelsman@wisc.edu
Jo Handelsman, PhD
Wisconsin Institute for Discovery
Simon Goldberg, PhD
Wisconsin Institute for Discovery
Interventions
  • Behavioral: Mindfulness Practice — Participants follow guided meditations in the Healthy Minds Program (HMP) mobile phone app for at least 15 min per day, for a total of 14 days.
  • Behavioral: Storytelling Workshop — Participants attend 1 (120 min) workshops, teaching them creative writing tools and giving them opportunities to apply those tools.
Study Locations (1 sites)
Wisconsin Institute for Discovery, Madison, Wisconsin 53715 United States
Eligibility Criteria
Inclusion Criteria: * 18 or older * Current graduate student in a Science, Technology, Engineering, and Math (STEM) field at the University of Wisconsin-Madison * No significant experience with mindfulness practice Exclusion Criteria: * Under 18 * Significant experience with mindfulness practice * Not a current graduate student in a STEM field at the University of Wisconsin-Madison
Conditions Major Depressive Disorder
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

Repetitive transcranial magnetic stimulation (rTMS) is a way of non-invasively stimulating specific brain networks and is an established treatment for Major Depressive Disorder (MDD). This proposal will reveal network mechanisms of the therapeutic effects of rTMS by investigating how stimulating each network specifically changes network connectivity and behavior. This will be done in a highly individualized manner in depressed and healthy patients, leading to more effective and more individualized treatments for depression.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Crossover Primary purpose: Other Masking/blinding: Double

Interventions / Regimen

  • Device: Intermittent Theta Burst Stimulation (iTBS) — iTBS is a form of non-invasive brain stimulation used to treat depression. It works on the principles of electromagnetic induction.

Primary Outcomes

  • Resting-state functional connectivity (FC) (1 hour)
  • Blood oxygenation level dependent (BOLD) activation (1 hour)
  • Applied Cognition-General Concerns scale (10 minutes)
  • Profile of Mood States Tension subscale (5 minutes)
  • Profile of Mood States Vigor subscale (5 minutes)
  • Profile of Mood States Dejection subscale (5 minutes)
  • State Shame and Guilt Scale (5-10 minutes)
  • Fawcett-Clark Pleasure Capacity Scale (5-10 minutes)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-03-12
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Collaborators: National Institute of Mental Health (NIMH)
Contact Information
Study Contact:
Mark Eldaief, MD
(617) 726-1728
meldaief@partners.org
Massachusetts General Hospital
Interventions
  • Device: Intermittent Theta Burst Stimulation (iTBS) — iTBS is a form of non-invasive brain stimulation used to treat depression. It works on the principles of electromagnetic induction.
Study Locations (1 sites)
Massachusetts General Hospital, Boston, Massachusetts 02129 United States
Eligibility Criteria
Inclusion Criteria for healthy participants: * 18-65 years of age * Capacity to provide informed consent form to participate in the study Inclusion Criteria for participants with Major Depressive Disorder (MDD): * 18-65 years of age * Capacity to provide informed consent form to participate in the study * Currently in a major depressive episode. Comorbid anxiety disorders and personality disorders will be allowed provided that MDD is the primary diagnosis. Exclusion Criteria for all participants: * Meeting criteria, in the past or currently, for bipolar affective disorder, hypomania or mania. * Meeting criteria, in the past or currently, for a primary psychotic disorder (e.g., schizophrenia). * Neurological conditions with known structural brain lesions, e.g., intracranial masses, multiple sclerosis. * Any personal history of seizures or a family history of epilepsy in a first-degree relative. * Metal in the body that is ferromagnetic or metallic injury to the eyes. * Implanted pacemakers, medication pumps, vagal stimulators, deep brain stimulators, or ventriculoperitoneal shunts, etc. * Substance abuse or dependence that is current and active within the last six months, as indicated by self-report (e.g., heroin, cocaine, methamphetamines). * Inability to meet the safety criteria for MRI scanning for any other reason. * Severe or unstable medical illness. * Currently pregnant, as assessed with urine pregnancy test in women of childbearing age.
Conditions Unipolar Depression
Phase NA
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

This study will test the efficacy of transcranial direct current stimulation (tDCS) combined with mindfulness, remotely-delivered using a telemedicine protocol in 25 adults with unipolar depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: transcranial direct current stimulation (tDCS) and mindfulness instruction — tDCS together with audio providing mindfulness instruction and music
  • Device: Sham tDCS and Mindfulness — Placebo electrical sitmulation and audio-guided mindfulness instruction

Primary Outcomes

  • Hamilton Depression Rating Scale (HDRS) (Week 4 and Week 7)
  • Blinding Integrity (Week 7)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-01
Completion: 2026-09-01
Eligibility
Age: 22 Years and older
Sex: ALL
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Soterix Medical
Contact Information
Study Contact:
Paul Thomas Researcher
18889908327
trials@soterixmedical.com
Paul Thomas
18889908327
trials@soterixmedical.com
Soterix Medical, Inc.
Interventions
  • Device: transcranial direct current stimulation (tDCS) and mindfulness instruction — tDCS together with audio providing mindfulness instruction and music
  • Device: Sham tDCS and Mindfulness — Placebo electrical sitmulation and audio-guided mindfulness instruction
Study Locations (1 sites)
Soterix Medical, Inc., Woodbridge, New Jersey 07095 United States
Eligibility Criteria
Inclusion Criteria: * Clinically stable patients that meet criteria for diagnosis of MDD according to DSM-V-TR and confirmed with the Mini International Neuropsychiatric interview * Currently experiencing a major depressive episode of at least 4 week's duration as part of a unipolar depression * QIDS-SR score \>11 on all three days of screening week (Days 1,3, 7) * Scored at least 17 (inclusive) on the HDRS-17 at trial entry * Any antidepressant medication is stable ≥ 30 days prior to HDRS-17 screening * Female patients are allowed if not pregnant and using a medically acceptable method of contraception, if of childbearing potential. Exclusion Criteria: * Failure to respond to at least 2 antidepressant medications * Drug or alcohol abuse or dependence in the preceding 3 months * Concurrent benzodiazepine medication * High suicide risk assessed during clinician screening at baseline interview. * Failure to respond to ECT treatment or rTMS treatment in this or any previous episode. * Current DSM-V-TR psychotic disorder * History of clinically defined neurological disorder or insult that may impact participation in this study as determined by study physician * Metal in the cranium or skull defects * Implanted pump, neurostimulator, cardiac pacemaker or defibrillator * Skin lesions on scalp at the proposed electrode sites * Pregnancy
Conditions Autism Spectrum Disorder, Psychological ...
Phase NA
Enrollment 77
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the feasibility of a culturally adapted, nurse-led Creating Opportunities for Parent Empowerment (COPE) intervention to improve the psychological wellbeing of primary caregivers of children with Autism Spectrum Disorder (ASD) in Pakistan. The study will use an exploratory sequential mixed-methods design comprising a qualitative needs assessment followed by a pilot randomized controlled feasibility trial. Qualitative interviews will identify caregivers' training needs and inform the cultural adaptation of the COPE intervention. Eligible caregivers will then be randomly assigned to either an intervention group receiving the culturally adapted COPE program in addition to routine care or a control group receiving routine care alone. The intervention consists of four weekly nurse-led sessions focusing on psychoeducation, cognitive restructuring, coping strategies, positive parenting, emotional regulation, and family resilience. Psychological wellbeing will be assessed using the Depression Anxiety Stress Scale-21 (DASS-21) at baseline and one month after the intervention. The study will also evaluate recruitment, retention, intervention adherence, acceptability, and implementation feasibility to inform the design of a future definitive randomized controlled trial.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Culturally Adapted Nurse-Led COPE Intervention — The intervention is a culturally adapted, nurse-led behavioral and psychoeducational program based on the Creating Opportunities for Parent Empowerment (COPE) framework. It is designed to improve the psychological wellbeing of primary caregivers of children with Autism Spectrum Disorder (ASD) by enhancing coping skills, emotional regulation, problem-solving abilities, and parenting confidence. The intervention comprises four weekly sessions of approximately 45 minutes each and includes education about ASD, cognitive restructuring, stress management, positive parenting strategies, guided problem-solving, and development of long-term coping and family resilience. The program is delivered by trained nurses using standardized educational materials, including presentations, audiovisual aids, and printed booklets.
  • Other: Routine Hospital Care — Participants receive the standard care routinely provided by the hospital for families of children with Autism Spectrum Disorder. No components of the culturally adapted nurse-led COPE intervention are provided during the study period.

Primary Outcomes

  • Change in Depression Score (Baseline and 1 month after completion of the intervention.)
  • Anxiety (Baseline and 1 month after completion of the intervention.)
  • Stress (Baseline and 1 month after completion of the intervention.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-15
Completion: 2027-05-25
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 77 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Khyber Medical University Peshawar
Collaborators: Children Hospital Faisalabad
Principal Investigators:
  • Zeenaf Aslam, RN, MSN,PHD* (PRINCIPAL_INVESTIGATOR) - Institute of Nursing Sciences, Khyber Medical University Peshawar
  • Dr Dildar Muhammad, PhD (PRINCIPAL_INVESTIGATOR) - Institute of Nursing Sciences, Khyber Medical University Peshawar
Contact Information
Study Contact:
Zeenaf Aslam, RN, MSN,PHD*
+92 332 6613345
zeenafch@gmail.com
Dr Syed Muhammad Shabbir Ali Naqvi, PhD*
+923460113227
coordinator.ctu@kmu.edu.pk
Zeenaf Aslam, RN,MSN,PhD*
+92 332 6613345
zeenafch@gmail.com
Children Hospital Complex and Institute of Child Health
Interventions
  • Behavioral: Culturally Adapted Nurse-Led COPE Intervention — The intervention is a culturally adapted, nurse-led behavioral and psychoeducational program based on the Creating Opportunities for Parent Empowerment (COPE) framework. It is designed to improve the psychological wellbeing of primary caregivers of children with Autism Spectrum Disorder (ASD) by enhancing coping skills, emotional regulation, problem-solving abilities, and parenting confidence. The intervention comprises four weekly sessions of approximately 45 minutes each and includes education about ASD, cognitive restructuring, stress management, positive parenting strategies, guided problem-solving, and development of long-term coping and family resilience. The program is delivered by trained nurses using standardized educational materials, including presentations, audiovisual aids, and printed booklets.
  • Other: Routine Hospital Care — Participants receive the standard care routinely provided by the hospital for families of children with Autism Spectrum Disorder. No components of the culturally adapted nurse-led COPE intervention are provided during the study period.
Study Locations (1 sites)
Children Hospital Complex and Institute of Child Health, Faisalābad, Punjab Province 38000 Pakistan
Eligibility Criteria
Inclusion Criteria: * Male or female primary caregivers aged 18 years or older. * Primary caregiver of a child with a confirmed diagnosis of Autism Spectrum Disorder (ASD). * Able to communicate in Urdu. * Willing and able to provide written informed consent. * Available to attend all intervention sessions and follow-up assessments. Exclusion Criteria: * Caregivers currently participating in another structured psychosocial, behavioral, or parenting intervention. * Caregivers with a diagnosed severe psychiatric illness or cognitive impairment that would interfere with participation. * Caregivers unable to communicate effectively in Urdu. * Caregivers who decline or are unable to provide informed consent. * Caregivers who are unavailable to complete the intervention or follow-up assessments.
Conditions Premature Infant, Mental Health Issue (E...
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

This study is being done to see if outcomes for both a premature infant's parents and the infant born prematurely who have spent time in the neonatal intensive care unit (NICU) can be improved through parent cognitive behavioral therapy (CBT) sessions.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Cognitive Behavioral Therapy — The intervention group will receive standard NICU and follow up care information plus a total of 5 CBT sessions split between the NICU and outpatient clinic visits post discharge from NICU. The CBT sessions will address PPCV in parents and parenting skills to address this. The CBT sessions will be standardized with a manual for study investigators to follow during sessions, and made with Dr. Richard Shaw from Stanford University, who wrote the prior CBT manual for anxiety, depression, and PTSD for NICU parents. Study staff will be trained to give the standardized CBT sessions using the manual via pilot sessions. There will be 3 CBT sessions given in the Parkland NICU before discharge and then 2 in the THRIVE follow up clinic at Children's Medical Center after discharge from the NICU.

Primary Outcomes

  • mean value score Vulnerable Baby Scale (VBSc) Score (difference in the mean value score of the VBSc scores of parents at baseline of the study (33 weeks post-menstrual age) versus at six to nine months of post-birth age)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2019-04-15
Completion: 2026-12-01
Eligibility
Age: Not reported
Sex: ALL
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Texas Southwestern Medical Center
Collaborators: Stanford University
Principal Investigators:
  • Margaret K Hoge, MD (PRINCIPAL_INVESTIGATOR) - UT Southwestern Medical Center Dallas
  • Roy Heyne, MD (STUDY_DIRECTOR) - UT Southwestern Medical Center Dallas
  • Richard J Shaw, MD (STUDY_DIRECTOR) - Stanford University
Contact Information
Study Contact:
Margaret K Hoge, MD
214-617-8439
margaret.hoge@utsouthwestern.edu
Roy Heyne, MD
roy.heyne@utsouthwestern.edu
Margaret K Hoge, MD
405-596-2075
margaret.hoge@utsouthwestern.edu
Parkland Health & Hospital System
Interventions
  • Behavioral: Cognitive Behavioral Therapy — The intervention group will receive standard NICU and follow up care information plus a total of 5 CBT sessions split between the NICU and outpatient clinic visits post discharge from NICU. The CBT sessions will address PPCV in parents and parenting skills to address this. The CBT sessions will be standardized with a manual for study investigators to follow during sessions, and made with Dr. Richard Shaw from Stanford University, who wrote the prior CBT manual for anxiety, depression, and PTSD for NICU parents. Study staff will be trained to give the standardized CBT sessions using the manual via pilot sessions. There will be 3 CBT sessions given in the Parkland NICU before discharge and then 2 in the THRIVE follow up clinic at Children's Medical Center after discharge from the NICU.
Study Locations (1 sites)
Parkland Health & Hospital System, Dallas, Texas 75235 United States
Eligibility Criteria
Inclusion Criteria: * Born at Parkland Hospital * English or Spanish speaking mother +/- father * ≤ 30.6 weeks gestation at birth * Survival to 33 weeks gestation Exclusion Criteria: * Significant congenital anomalies * Child Protective Services (CPS) involvement or foster care placement -- Prior enrollment in this PreVNT study for an older sibling.